{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:38:11Z","timestamp":1782772691075,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the severity of coronavirus disease 2019 (COVID-19) tends to be lower in children, it can still lead to severe illness, particularly among those with chronic medical conditions. While remdesivir (RDV) is one of the few approved antiviral treatments for COVID-19 in children in many countries, the available data on the safety of RDV in this population is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To address this knowledge gap, a multicenter study involving 65 patients retrospectively analyzed the clinical data from individuals aged\n                      <jats:underline>&lt;<\/jats:underline>\n                      18 who were hospitalized due to severe COVID-19 (defined as SpO\n                      <jats:sub>2<\/jats:sub>\n                      &lt; 94% or requiring supplemental oxygen) and received at least one dose of RDV. Additionally, the study encompassed 22 patients with mild-moderate COVID-19 who were considered at high risk of developing severe disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen children (29%) experienced mild-to-moderate adverse events (AEs) attributed to RDV, including transaminitis in 20% of children, bradycardia in 8%, and hypotension in 5%. AEs did not require discontinuation of RDV, except in one patient who developed premature ventricular contractions. The rate of AEs did not differ between patients with severe COVID-19 and those with mild-moderate COVID-19 but at high risk for severe disease. All but one patient were discharged within 23 days of admission, and no fatalities were recorded. Among high-risk patients with mild-moderate disease, only 2 (9%) progressed to the point of needing supplemental oxygen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggests that RDV is safe in children, with no reported serious AEs. However, the absence of a control group limits the extent to which conclusions can be drawn. RDV may contribute to clinical improvement, particularly in high-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40348-024-00175-9","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:02:23Z","timestamp":1708491743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study"],"prefix":"10.1186","volume":"11","author":[{"given":"Abigail","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Bakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"175_CR1","unstructured":"Demographic Trends of COVID-19 cases and deaths in the US reported to CDC. Centers for Disease Control and Prevention. Accessed August 25, 2023. https:\/\/covid.cdc.gov\/covid-data-tracker\/#demographics."},{"issue":"11","key":"175_CR2","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jama.2021.2091","volume":"325","author":"LR Feldstein","year":"2021","unstructured":"Feldstein LR, Tenforde MW, Friedman KG et al (2021) Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 325(11):1074\u20131087. https:\/\/doi.org\/10.1001\/jama.2021.2091","journal-title":"JAMA."},{"key":"175_CR3","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Dambrauskas S, V\u00e1squez-Hoyos P, Camporesi A et al (2020) Pediatric critical care and COVID-19. Pediatrics. 146(3). https:\/\/doi.org\/10.1542\/peds.2020-1766","DOI":"10.1542\/peds.2020-1766"},{"issue":"2","key":"175_CR4","doi-asserted-by":"publisher","first-page":"e2143151","DOI":"10.1001\/jamanetworkopen.2021.43151","volume":"5","author":"B Martin","year":"2022","unstructured":"Martin B, DeWitt PE, Russell S et al (2022) Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US National COVID Cohort Collaborative. JAMA Netw Open. 5(2):e2143151. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.43151","journal-title":"JAMA Netw Open."},{"key":"175_CR5","doi-asserted-by":"publisher","unstructured":"Woodruff RC, Campbell AP, Taylor CA et al (2022) Risk factors for severe COVID-19 in children. Pediatrics. 149(1). https:\/\/doi.org\/10.1542\/peds.2021-053418","DOI":"10.1542\/peds.2021-053418"},{"issue":"5","key":"175_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","volume":"60","author":"R Humeniuk","year":"2021","unstructured":"Humeniuk R, Mathias A, Kirby BJ et al (2021) Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor. Clin Pharmacokinet. 60(5):569\u2013583. https:\/\/doi.org\/10.1007\/s40262-021-00984-5","journal-title":"Clin Pharmacokinet."},{"key":"175_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bbrc.2020.11.043","volume":"538","author":"MG Santoro","year":"2021","unstructured":"Santoro MG, Carafoli E (2021) Remdesivir: from ebola to COVID-19. Biochem Biophys Res Commun. 538:145\u2013150. https:\/\/doi.org\/10.1016\/j.bbrc.2020.11.043","journal-title":"Biochem Biophys Res Commun."},{"issue":"1","key":"175_CR8","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1093\/cid\/ciab1035","volume":"75","author":"BT Garibaldi","year":"2022","unstructured":"Garibaldi BT, Wang K, Robinson ML et al (2022) Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study. Clin Infect Dis. 75(1):e516\u2013e524. https:\/\/doi.org\/10.1093\/cid\/ciab1035","journal-title":"Clin Infect Dis."},{"issue":"19","key":"175_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of COVID-19 - final report. N Engl J Med. 383(19):1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med."},{"issue":"10339","key":"175_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","volume":"399","author":"Consortium WST","year":"2022","unstructured":"Consortium WST (2022) Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 399(10339):1941\u20131953. https:\/\/doi.org\/10.1016\/S0140-6736(22)00519-0","journal-title":"Lancet."},{"key":"175_CR11","doi-asserted-by":"publisher","first-page":"204209862110425","DOI":"10.1177\/20420986211042517","volume":"12","author":"C Santenna","year":"2021","unstructured":"Santenna C, Vidyasagar K, Amarneni KC et al (2021) The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis. Ther Adv Drug Saf. 12:20420986211042516. https:\/\/doi.org\/10.1177\/20420986211042517","journal-title":"Ther Adv Drug Saf."},{"issue":"3","key":"175_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12012-021-09703-9","volume":"22","author":"M Nabati","year":"2022","unstructured":"Nabati M, Parsaee H (2022) Potential cardiotoxic effects of remdesivir on cardiovascular system: a literature review. Cardiovasc Toxicol. 22(3):268\u2013272. https:\/\/doi.org\/10.1007\/s12012-021-09703-9","journal-title":"Cardiovasc Toxicol."},{"key":"175_CR13","unstructured":"FDA\u2019s approval of Veklury (remdesivir) for the treatment of COVID-19\u2014the science of safety and effectiveness (2020) U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-approval-veklury-remdesivirtreatment-covid-19-science-safety-and-effectiveness"},{"key":"175_CR14","unstructured":"Phase 2\/3 Interim data evaluating the safety, tolerability and clinical outcomes of Veklury\u00ae (remdesivir) in pediatric patients with COVID-19 presented at CROI 2022. Gilead Sciences, Inc; 2022. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2022\/2\/phase-23-interim-data-evaluating-the-safety-tolerability-and-clinical-outcomes-of-veklury-remdesivir-in-pediatric-patients-with-covid19-presente."},{"issue":"4","key":"175_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/INF.0000000000003814","volume":"42","author":"AM Samuel","year":"2023","unstructured":"Samuel AM, Hacker LL, Zebracki J et al (2023) Remdesivir use in pediatric patients for SARS-CoV-2 treatment: single academic center study. Pediatr Infect Dis J. 42(4):310\u2013314. https:\/\/doi.org\/10.1097\/INF.0000000000003814","journal-title":"Pediatr Infect Dis J."},{"key":"175_CR16","doi-asserted-by":"publisher","unstructured":"Goldman DL, Aldrich ML, Hagmann SHF et al (2021) Compassionate use of remdesivir in children with severe COVID-19. Pediatrics. 147(5). https:\/\/doi.org\/10.1542\/peds.2020-047803","DOI":"10.1542\/peds.2020-047803"},{"key":"175_CR17","unstructured":"Coronavirus (COVID-19) Update: FDA approves first COVID-19 treatment for young children. U.S. Food and Drug Administration; 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children."},{"issue":"12","key":"175_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1248\/bpb.b22-00470","volume":"45","author":"S Manabe","year":"2022","unstructured":"Manabe S, Mizuno S, Jinda T, Kasai M (2022) Safety of remdesivir in 20 children with COVID-19-case series. Biol Pharm Bull. 45(12):1853\u20131856. https:\/\/doi.org\/10.1248\/bpb.b22-00470","journal-title":"Biol Pharm Bull."},{"key":"175_CR19","doi-asserted-by":"publisher","unstructured":"Jugulete G, Luminos M, Pavelescu C, Meri\u0219escu MM (2023) Remdesivir efficacy and tolerability in children with COVID-19-associated allergic comorbidities such as asthma, allergic rhinitis, and atopic dermatitis. Children (Basel). 10(5). https:\/\/doi.org\/10.3390\/children10050810","DOI":"10.3390\/children10050810"},{"issue":"4","key":"175_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00431-020-03876-1","volume":"180","author":"A M\u00e9ndez-Echevarr\u00eda","year":"2021","unstructured":"M\u00e9ndez-Echevarr\u00eda A, P\u00e9rez-Mart\u00ednez A, Gonzalez Del Valle L et al (2021) Compassionate use of remdesivir in children with COVID-19. Eur J Pediatr. 180(4):1317\u20131322. https:\/\/doi.org\/10.1007\/s00431-020-03876-1","journal-title":"Eur J Pediatr."},{"key":"175_CR21","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Accessed October 13, 2023. https:\/\/www.covid19treatmentguidelines.nih.gov."},{"issue":"8 Suppl","key":"175_CR22","first-page":"I291","volume":"102","author":"Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care","year":"2000","unstructured":"Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care (2000) Part 10: pediatric advanced life support. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 102(8 Suppl):I291\u2013I342","journal-title":"Circulation."},{"key":"175_CR23","doi-asserted-by":"publisher","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 140(3). https:\/\/doi.org\/10.1542\/peds.2017-1904","DOI":"10.1542\/peds.2017-1904"},{"key":"175_CR24","unstructured":"PALS Bradycardia Algorithm. ACLS Medical Training. https:\/\/www.aclsmedicaltraining.com\/pediatric-bradycardiasequence\/"},{"key":"175_CR25","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.\u00a0(2017) U.S. Department of Health and Human Services. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"4","key":"175_CR26","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 120(4):c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract."},{"issue":"2","key":"175_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 30(2):239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther."},{"key":"175_CR28","unstructured":"Hepatocyte Injury Index (HIX) Calculator. Massachusetts General Hospital; Accessed January 31, 2024. https:\/\/hix.massgeneral.org\/."},{"issue":"3","key":"175_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4254\/wjh.v15.i3.353","volume":"15","author":"YF Yun","year":"2023","unstructured":"Yun YF, Feng ZY, Zhang JJ (2023) COVID-19 and liver dysfunction in children: current views and new hypotheses. World J Hepatol. 15(3):353\u2013363. https:\/\/doi.org\/10.4254\/wjh.v15.i3.353","journal-title":"World J Hepatol."},{"key":"175_CR30","doi-asserted-by":"publisher","first-page":"104955","DOI":"10.1016\/j.antiviral.2020.104955","volume":"184","author":"SW Choi","year":"2020","unstructured":"Choi SW, Shin JS, Park SJ et al (2020) Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. 184:104955. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104955","journal-title":"Antiviral Res."},{"issue":"4","key":"175_CR31","doi-asserted-by":"publisher","first-page":"e0266737","DOI":"10.1371\/journal.pone.0266737","volume":"17","author":"R Raina","year":"2022","unstructured":"Raina R, Mawby I, Chakraborty R et al (2022) Acute kidney injury in COVID-19 pediatric patients in North America: analysis of the virtual pediatric systems data. PLoS One. 17(4):e0266737. https:\/\/doi.org\/10.1371\/journal.pone.0266737","journal-title":"PLoS One."},{"key":"175_CR32","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.clinsp.2023.100200","volume":"78","author":"G Shams","year":"2023","unstructured":"Shams G, Kazemi A, Jafaryan K, Morowvat MH, Peymani P, Karimzadeh I (2023) Acute kidney injury in COVID-19 patients receiving remdesivir: a systematic review and meta-analysis of randomized clinical trials. Clinics (Sao Paulo). 78:100200. https:\/\/doi.org\/10.1016\/j.clinsp.2023.100200","journal-title":"Clinics (Sao Paulo)."},{"issue":"4","key":"175_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R et al (2022) Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 386(4):305\u2013315. https:\/\/doi.org\/10.1056\/NEJMoa2116846","journal-title":"N Engl J Med."},{"key":"175_CR34","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.15585\/mmwr.mm7036e2","volume":"70","author":"M Delahoy","year":"2021","unstructured":"Delahoy M, Ujamaa D, Whitaker M et al (2021) Hospitalizations associated with COVID-19 among children and adolescents \u2014 COVID-NET, 14 States, March 1, 2020\u2013August 14, 2021. MMWR Morb Mortal Wkly Rep. 70:1255\u20131260","journal-title":"MMWR Morb Mortal Wkly Rep."}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-024-00175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-024-00175-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-024-00175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:08:50Z","timestamp":1708492130000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-024-00175-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1186\/s40348-024-00175-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3649863\/v1","asserted-by":"object"}]},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University of Illinois College of Medicine at Peoria approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}